Abstract
张丽,张卫,吕静静,张继娟,刘甲野,颜丙玉,冯艺,梁晓峰,崔富强,王富珍,张国民,徐爱强.5μg和10μg重组乙型肝炎疫苗初次免疫正常应答和高应答新生儿5年抗体持久性比较[J].Chinese journal of Epidemiology,2017,38(9):1156-1160
5μg和10μg重组乙型肝炎疫苗初次免疫正常应答和高应答新生儿5年抗体持久性比较
Comparison of antibody persistence after primary immunization with 5 μg and 10 μg recombinant hepatitis B vaccine among newborns with normal and high response:a five-year following-up
Received:January 16, 2017  
DOI:10.3760/cma.j.issn.0254-6450.2017.09.002
KeyWord: 乙型肝炎疫苗  免疫剂量  抗体持久性  新生儿
English Key Word: Hepatitis B vaccine  Vaccine dosage  Antibody persistence  Newborn
FundProject:国家科技重大专项(2012ZX10002-001,2013ZX10004-902);山东省医药卫生科技发展计划(2009QZ017,2014WS0373);山东省泰山学者工程(TS201511105)
Author NameAffiliationE-mail
Zhang Li Department of Immunization Programme, Shandong Provincial Center for Disease Control and Prevention, Ji'nan 250014, China  
Zhang Wei Department of Planned Immunization Programme, Beijing Center for Disease Control and Prevention, Beijing 100013, China  
Lyu Jingjing Department of Immunization Programme, Shandong Provincial Center for Disease Control and Prevention, Ji'nan 250014, China  
Zhang Jijuan Pharmacy Department of Shandong Tumor Hospital, Ji'nan 250117, China  
Liu Jiaye Department of Immunization Programme, Shandong Provincial Center for Disease Control and Prevention, Ji'nan 250014, China  
Yan Bingyu Department of Immunization Programme, Shandong Provincial Center for Disease Control and Prevention, Ji'nan 250014, China  
Feng Yi Department of Immunization Programme, Shandong Provincial Center for Disease Control and Prevention, Ji'nan 250014, China  
Liang Xiaofeng Department of Immunization Programme, Chinese Center for Disease Control and Prevention, Beijing 100050, China  
Cui Fuqiang Department of Immunization Programme, Chinese Center for Disease Control and Prevention, Beijing 100050, China  
Wang Fuzhen Department of Immunization Programme, Chinese Center for Disease Control and Prevention, Beijing 100050, China  
Zhang Guomin Department of Immunization Programme, Chinese Center for Disease Control and Prevention, Beijing 100050, China  
Xu Aiqiang Department of Immunization Programme, Shandong Provincial Center for Disease Control and Prevention, Ji'nan 250014, China aqxuepi@163.com 
Hits: 4195
Download times: 2148
Abstract:
      目的 比较5 μg和10 μg乙型肝炎疫苗(HepB)初次免疫(初免)正常应答和高应答新生儿初免后5年的抗体持久性。方法 选用5 μg(重组啤酒酵母)和10 μg(重组汉逊酵母)HepB,按照"0-1-6"程序完成3剂次初免的新生儿,并在接种第3剂次后1~6个月(T0)和5年(T1)后分别采集静脉血,采用化学发光微粒子免疫分析法(CMIA)定量检测抗-HBs,比较两剂量接种后正常应答和高应答(T0时抗-HBs ≥ 100 mIU/ml)者T1时的抗体阳性率(抗-HBs ≥ 10 mIU/ml)和平均抗体浓度(GMC);通过多因素分析探讨接种剂量与抗体持久性的关系。结果 HepB 5 μg组和10 μg组分别共有1 883名和1 495名观察对象纳入分析,T1时抗-HBs阳性率分别为49.92%(943/1 883)和75.92%(1 135/1 495),差异有统计学意义(χ2=237.75,P<0.001);GMC分别为10.23(95%CI:9.38~11.16)mIU/ml和28.91(95%CI:26.65~31.35)mIU/ml,差异有统计学意义(F=280.36,P<0.001)。10 μg组T1时抗-HBs阴转者抗-HBs滴度分布与5 μg组的差异有统计学意义(χ2=39.75,P<0.001)。多因素分析显示,排除其他因素影响后,HepB初免剂量与T1时抗-HBs阳性率和抗-HBs滴度均独立相关[P<0.001,OR=1.44(95%CI:1.20~1.73);P<0.001,β=0.27(95%CI:0.14~0.40)]。结论 新生儿使用10 μg重组HepB初免后5年抗-HBs持久性优于5 μg重组HepB。
English Abstract:
      Objective To compare the antibody persistence 5 years after primary immunization with 5 μg and 10 μg recombinant hepatitis B vaccine (HepB) among newborns with normal and high response. Methods Newborns who completed three doses of 5 μg HepB made by recombinant dexyribonucleic acid technique in Saccharomyces (HepB-SC) or 10 μg HepB made by recombinant dexyribonucleic acid technique in Hansenula polymorpha (HepB-HP) were recruited. Standardized questionnaire was used and blood samples were collected 1-6 months (T0) and five years (T1) after the third dose respectively. The titer of anti-HBs was detected by chemiluminescence microparticle imunoassay (CMIA). Those who achieved normal or high antibody response (anti-HBs titer ≥ 100 mIU/ml) were included in the study and the positive rate (≥ 10 mIU/ml) and titer of anti-HBs at T1 were compared between 5 μg HepB group and 10 μg HepB group. Multivariable analysis was conducted to identify the independent factors associated with the antibody persistence. Results The positive rate of anti-HBs at T1 was 49.92% (943/1 883) and 75.92% (1 135/1 495) respectively in 5 μg HepB group and 10μg HepB group, the difference was significant (χ2=237.75, P<0.001). The anti-HBs geometric mean concentrations at T1 were 10.23 mIU/ml (95%CI:9.38-11.16) and 28.91 mIU/ml (95%CI:26.65-31.35) in the two groups respectively, the difference was also significant (F=280.36, P<0.001). Among those whose anti-HBs titer was <10 mIU/ml at T1, the distributions of anti-HBs titer were significantly different between 5 μg HepB group and 10 μg HepB group (χ2=39.75, P<0.001). The multivariable analysis showed that dosage of HepB was independently associated with both positive rate and titer of anti-HBs at T1 after excluding the other factors[P<0.001, OR=1.44 (95%CI:1.20-1.73); P<0.001, β=0.27 (95%CI:0.14-0.40)]. Conclusion Five year anti-HBs persistence after primary immunization with 10 μg HepB might be better than that after primary immunization with 5 μg HepB among infants who achieved normal or high anti-HBs response after primary HepB immunization.
View Fulltext   Html FullText     View/Add Comment  Download reader
Close